-
Chapter
Estrogenic Recruitment Followed by Chemotherapy in Breast Cancer: Experimental and Clinical Results
In the last decade the chemotherapy of metastatic breast cancer has reached a plateau in terms of response rate and survival [1]. The knowledge of hormone dependency of at least a proportion of breast tumors h...
-
Chapter and Conference Paper
Double 5-FU modulation with folinic acid and recombinant alfa2b-Interferon : a phase I–II study in metastatic colorectal cancer patients
5-Fluorouracil (5-FU) is the most widely employed chemotherapeutic agent for patients with metastatic colorectal cancer (MCC) and objective response rates (ORR) are achievable in approximately 10–20 Wo of trea...
-
Article
Symptomatic myopathy during interferon alfa therapy for chronic myelogenous leukemia
-
Article
Open AccessHypersensitivity reactions related to oxaliplatin (OHP)
Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions related to oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected ...
-
Article
Open AccessA randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
Docetaxel (75 mg m−2 3-weekly) is standard second-line treatment in advanced non-small-cell lung cancer (NSCLC) with significant toxicity. To verify whether a weekly schedule (33.3 mg m−2 for 6 weeks) improved qu...
-
Article
Open AccessAdjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
The aim of the study was to determine whether modulation of 5-fluorouracil (FU) by methotrexate (MTX) improves survival compared to FU+6-s-leucovorin (LV) following potentially curative resection of stage II and ...
-
Article
Open AccessErratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
A Sobrero1, G Frassineti2, A Falcone3, L Dogliotti4, R Rosso5, F Di Costanzo6 and P Bruzzi5 on behalf of the INTACC7 Correction to: British Journal of Cancer (2004) 92, 24–29. doi:10.1038/sj.bjc.6602276 Owing ...
-
Article
Open AccessEpirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study
The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small...
-
Article
Open AccessPhase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxe...
-
Article
Open AccessFirst line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
This multicenter phase II study evaluated, in chemonaive patients with stage IIIB–IV NSCLC, age ⩾70 and with a performance status 0–2, the activity, efficacy and tolerability of planned sequential administrati...
-
Article
Open AccessA pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
The pharmacokinetics (PK) and pharmacodynamics (PD) of metronomic irinotecan have not been studied in cancer patients. The aim of the study is to investigate the PK/PD profile of irinotecan/SN-38 administered ...
-
Article
Open AccessAntiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
Metronomic chemotherapy refers to the administration of chemotherapy at low, nontoxic doses on a frequent schedule with no prolonged breaks. The aim of the study is to rationally develop a CPT-11 metronomic re...
-
Article
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
The primary end point of the study was the analysis of associations between polymorphisms with putative influence on 5-fluorouracil/irinotecan activity and progression-free survival (PFS) of patients with adva...
-
Article
Open AccessLiver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC). The t...
-
Article
Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model
We aimed to investigate the prognostic significance of several baseline variables in stage IIIB-IV non-small cell lung cancer to create a model based on independent prognostic factors.
-
Article
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis. Two single nucleotide polymorphisms in the IL-1RA gene (rs4251961 T/C and rs579543 C/T) influence IL...
-
Article
Open AccessMucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
The objective of this study was to investigate the efficacy of first-line chemotherapy containing irinotecan and/or oxaliplatin in patients with advanced mucinous colorectal cancer. Prognostic factors associat...
-
Article
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in...
-
Article
Open AccessA multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substitut...
-
Article
Open AccessDo we need biopsies of metastases for colorectal cancer patients?